Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Simple item page
dc.contributor.authorMunoz-Martinez, Sergio
dc.contributor.authorSapena, Victor
dc.contributor.authorForner, Alejandro
dc.contributor.authorNault, Jean-Charles
dc.contributor.authorSapisochin, Gonzalo
dc.contributor.authorRimassa, Lorenza
dc.contributor.authorSangro, Bruno
dc.contributor.authorBruix, Jordi
dc.contributor.authorSanduzzi-Zamparelli, Marco
dc.contributor.authorHolowko, Waclaw
dc.contributor.authorEl Kassas, Mohamed
dc.contributor.authorMocan, Tudor
dc.contributor.authorBouattour, Mohamed
dc.contributor.authorMerle, Philippe
dc.contributor.authorHoogwater, Frederik J. H.
dc.contributor.authorAlqahtani, Saleh A.
dc.contributor.authorReeves, Helen L.
dc.contributor.authorPinato, David J.
dc.contributor.authorGiorgakis, Emmanouil
dc.contributor.authorMeyer, Tim
dc.contributor.authorVilladsen, Gerda Elisabeth
dc.contributor.authorWege, Henning
dc.contributor.authorSalati, Massimiliano
dc.contributor.authorMinguez, Beatriz
dc.contributor.authorDi Costanzo, Giovan Giuseppe
dc.contributor.authorRoderburg, Christoph
dc.contributor.authorTacke, Frank
dc.contributor.authorVarela, Maria
dc.contributor.authorGalle, Peter R.
dc.contributor.authorAlvares-da-Silva, Mario Reis
dc.contributor.authorTrojan, Joerg
dc.contributor.authorBridgewater, John
dc.contributor.authorCabibbo, Giuseppe
dc.contributor.authorToso, Christian
dc.contributor.authorLachenmayer, Anja
dc.contributor.authorCasadei-Gardini, Andrea
dc.contributor.authorToyoda, Hidenori
dc.contributor.authorLuedde, Tom
dc.contributor.authorVillani, Rosanna
dc.contributor.authorMatilla Pena, Ana Maria
dc.contributor.authorGuedes Leal, Cassia Regina
dc.contributor.authorRonzoni, Monica
dc.contributor.authorDelgado, Manuel
dc.contributor.authorPerello, Christie
dc.contributor.authorPascual, Sonia
dc.contributor.authorLuis Lledo, Jose
dc.contributor.authorArgemi, Josepmaria
dc.contributor.authorBasu, Bristi
dc.contributor.authorda Fonseca, Leonardo
dc.contributor.authorAcevedo, Juan
dc.contributor.authorSiebenhuener, Alexander R.
dc.contributor.authorBraconi, Chiara
dc.contributor.authorMeyers, Brandon M.
dc.contributor.authorGranito, Alessandro
dc.contributor.authorSala, Margarita
dc.contributor.authorRodriguez-Lope, Carlos
dc.contributor.authorBlaise, Lorraine
dc.contributor.authorRomero-Gomez, Manuel
dc.contributor.authorPinero, Federico
dc.contributor.authorGomez, Dhanny
dc.contributor.authorMello, Vivianne
dc.contributor.authorPinheiro Alves, Rogerio Camargo
dc.contributor.authorFranca, Alex
dc.contributor.authorBranco, Fernanda
dc.contributor.authorBrandi, Giovanni
dc.contributor.authorPereira, Gustavo
dc.contributor.authorColl, Susanna
dc.contributor.authorGuarino, Maria
dc.contributor.authorBenitez, Carlos
dc.contributor.authorMargarita Anders, Maria
dc.contributor.authorBandi, Juan C.
dc.contributor.authorVergara, Mercedes
dc.contributor.authorCalvo, Mariona
dc.contributor.authorPeck-Radosavljevic, Markus
dc.contributor.authorGarcia-Juarez, Ignacio
dc.contributor.authorCardinale, Vincenzo
dc.contributor.authorLozano, Mar
dc.contributor.authorGambato, Martina
dc.contributor.authorOkolicsanyi, Stefano
dc.contributor.authorMorales-Arraez, Dalia
dc.contributor.authorElvevi, Alessandra
dc.contributor.authorMunoz, Alberto E.
dc.contributor.authorLue, Alberto
dc.contributor.authorIavarone, Massimo
dc.contributor.authorReig, Maria
dc.date.accessioned2025-01-20T22:22:39Z
dc.date.available2025-01-20T22:22:39Z
dc.date.issued2021
dc.description.abstractBackground & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.
dc.description.abstractMethods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.
dc.description.abstractResults: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).
dc.description.abstractConclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.
dc.description.abstractLay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
dc.fuente.origenWOS
dc.identifier.eissn2589-5559
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94683
dc.identifier.wosidWOS:000658290100009
dc.issue.numero3
dc.language.isoen
dc.revistaJhep reports
dc.rightsacceso restringido
dc.subjectCOVID-19
dc.subjectHepatocellular carcinoma
dc.subjectCholangiocarcinoma
dc.subjectLiver cancer
dc.subjectManagement
dc.subjectClinical trials
dc.subjectNurses
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAssessing the impact of COVID-19 on liver cancer management (CERO-19)
dc.typeartículo
dc.volumen3
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas